Key result
AnchorMan proves noninferior to Watchman 2.5 for 12-month clinical success and LAA occlusion.
Why the study?
Percutaneous left atrial appendage closure is an alternative to oral anticoagulation, and the study evaluated the safety and efficacy of the novel AnchorMan device compared with Watchman 2.5.
Does left atrial appendage closure with the AnchorMan device improve clinical success compared to the Watchman 2.5 device in patients with non-valvular atrial fibrillation at high risk of ischaemic stroke?
RCT
Open-label
1:1
Yes
Does left atrial appendage closure with the AnchorMan device improve clinical success compared to the Watchman 2.5 device in patients with non-valvular atrial fibrillation at high risk of ischaemic stroke?
The novel AnchorMan LAA closure device is non-inferior to the Watchman 2.5 device for clinical success and LAA occlusion at 12 months in patients with non-valvular AF at high risk of stroke.
Answers are grounded in this paper and cite their sources.
Supports AnchorMan as alternative to Watchman for LAA closure; extends device options in high-risk nonvalvular AF.
BACKGROUND: Percutaneous closure of the left atrial appendage (LAA) is an alternative to chronic oral anticoagulation to reduce stroke risk in patients with non-valvular atrial fibrillation (AF). AIMS: The SAFE-PROTECT trial was designed to evaluate the safety and efficacy of the AnchorMan, a novel LAA closure device, compared with the Watchman 2.5 device for patients with AF at high risk of ischaemic stroke. METHODS: SAFE-PROTECT was a multicentre, open-label, non-inferiority trial of patients with non-valvular AF at high risk of ischaemic stroke, randomised 1:1 to LAA closure with the AnchorMan or the Watchman device. The 12-month primary endpoint was clinical success (freedom from ischaemic/haemorrhagic stroke, systemic embolism, cardiovascular or unexplained death); the secondary efficacy endpoint was echocardiography-defined LAA occlusion (peridevice leak <5 mm) at 12 months. RESULTS: =not applicable). The rates of all-cause death, stroke, major bleeding, and device-related complications were low and similar between groups. CONCLUSIONS: Among patients with non-valvular AF at high risk of ischaemic stroke, the AnchorMan device met its prespecified non-inferiority primary clinical success and secondary LAA occlusion endpoints compared with the Watchman 2.5 device. CLINICALTRIALS: gov: NCT04479722.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an RCT in Non-valvular atrial fibrillation. AnchorMan device vs. Watchman 2.5 device was evaluated on Clinical success (freedom from ischaemic/haemorrhagic stroke, systemic embolism, cardiovascular or unexplained death). Left atrial appendage closure with the AnchorMan device was noninferior to the Watchman 2.5 device for clinical success and LAA occlusion at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: